These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 30427812)

  • 21. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
    Ballard ED; Luckenbaugh DA; Richards EM; Walls TL; Brutsché NE; Ameli R; Niciu MJ; Vande Voort JL; Zarate CA
    J Psychiatr Res; 2015 Sep; 68():68-73. PubMed ID: 26228403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral Ketamine for Depression: A Systematic Review.
    Rosenblat JD; Carvalho AF; Li M; Lee Y; Subramanieapillai M; McIntyre RS
    J Clin Psychiatry; 2019 Apr; 80(3):. PubMed ID: 30995364
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
    Bobo WV; Vande Voort JL; Croarkin PE; Leung JG; Tye SJ; Frye MA
    Depress Anxiety; 2016 Aug; 33(8):698-710. PubMed ID: 27062450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up.
    Kwon JH; Sim WS; Hong JP; Song IS; Lee JY
    J Clin Pharm Ther; 2018 Aug; 43(4):581-583. PubMed ID: 29372569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
    McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
    J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline cognitive function predicts full remission of suicidal symptoms among patients with treatment-resistant depression and strong suicidal ideation after low-dose ketamine infusion.
    Lin WC; Su TP; Li CT; Wu HJ; Tsai SJ; Bai YM; Tu PC; Chen MH
    J Psychopharmacol; 2023 Aug; 37(8):795-801. PubMed ID: 37332247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
    Akiskal HS; Benazzi F; Perugi G; Rihmer Z
    J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose ketamine for treatment resistant depression in an academic clinical practice setting.
    Feifel D; Malcolm B; Boggie D; Lee K
    J Affect Disord; 2017 Oct; 221():283-288. PubMed ID: 28666206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Efficacy of Intranasal Esketamine in Treatment-Resistant Major Depression: A Systematic Review.
    Capuzzi E; Caldiroli A; Capellazzi M; Tagliabue I; Marcatili M; Colmegna F; Clerici M; Buoli M; Dakanalis A
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
    JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients.
    Banov MD; Landrum RE; Moore MB; Szabo ST
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):594-599. PubMed ID: 34411009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New use for an old drug: oral ketamine for treatment-resistant depression.
    Swiatek KM; Jordan K; Coffman J
    BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27489070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous arketamine for treatment-resistant depression: open-label pilot study.
    Leal GC; Bandeira ID; Correia-Melo FS; Telles M; Mello RP; Vieira F; Lima CS; Jesus-Nunes AP; Guerreiro-Costa LNF; Marback RF; Caliman-Fontes AT; Marques BLS; Bezerra MLO; Dias-Neto AL; Silva SS; Sampaio AS; Sanacora G; Turecki G; Loo C; Lacerda ALT; Quarantini LC
    Eur Arch Psychiatry Clin Neurosci; 2021 Apr; 271(3):577-582. PubMed ID: 32078034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of melancholic features on positive and negative suicidal ideation in patients with treatment-resistant depression and strong suicidal ideation receiving low-dose ketamine infusion.
    Chen MH; Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC
    Eur Arch Psychiatry Clin Neurosci; 2024 Jun; 274(4):759-766. PubMed ID: 38052767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
    Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
    Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
    J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Concurrent Treatment With Intravenous Ketamine and an Irreversible Monoamine Oxidase Inhibitor for Treatment-Resistant Depression Without Hypertensive Crises.
    Wang JCC; Swainson J
    J Clin Psychopharmacol; 2020; 40(5):515-517. PubMed ID: 32740556
    [No Abstract]   [Full Text] [Related]  

  • 39. Role of klotho on antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression and suicidal ideation.
    Chen MH; Bai YM; Wu HJ; Li CT; Lin WC; Tsai SJ; Su TP; Tu PC
    J Affect Disord; 2023 Nov; 340():471-475. PubMed ID: 37579883
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance Ketamine Therapy for Treatment-Resistant Depression.
    Archer S; Chrenek C; Swainson J
    J Clin Psychopharmacol; 2018 Aug; 38(4):380-384. PubMed ID: 29912788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.